Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SKL2001 是一种Wnt/β-catenin 信号通路的激动剂,具有抗肿瘤作用。它能够破坏 Axin/β-catenin 相互作用,稳定细胞内 β-catenin。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 152 | 现货 | ||
5 mg | ¥ 339 | 现货 | ||
10 mg | ¥ 547 | 现货 | ||
25 mg | ¥ 1,130 | 现货 | ||
50 mg | ¥ 1,970 | 现货 | ||
100 mg | ¥ 3,580 | 现货 | ||
200 mg | ¥ 5,250 | 现货 | ||
500 mg | ¥ 7,960 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 593 | 现货 |
产品描述 | SKL2001, an agonist of the Wnt/β-catenin pathway, can disrupt the Axin/β-catenin interaction. |
体外活性 | SKL2001 upregulated β-catenin responsive transcription by increasing the intracellular β-catenin protein level and inhibited the phosphorylation of β-catenin at residues Ser33/37/Thr41 and Ser45, which would mark it for proteasomal degradation, without affecting CK1 and GSK-3β enzyme activities. SKL2001 disrupted the Axin/β-catenin interaction, which is a critical step for CK1- and GSK-3β-mediated phosphorylation of β-catenin at Ser33/37/Thr41 and Ser45. The treatment of mesenchymal stem cells with SKL2001 promoted osteoblastogenesis and suppressed adipocyte differentiation, both of which were accompanied by the activation of Wnt/β-catenin pathway. SKL2001 did not affect either NF-κB or p53 reporter activity and inhibits β-catenin phosphorylation without affecting GSK-3β activity[1]. |
细胞实验 | The HEK293 reporter and control cell lines were established. The HEK293 reporter cells were inoculated into 384-well plates at 10 000 cells per well and grown for 24 h. Next, each compound in the chemical library (~270 000) was added to at a final concentration of 20 μM. After 15 h, the plates were assayed for firefly luciferase activity.(Only for Reference) |
分子量 | 286.29 |
分子式 | C14H14N4O3 |
CAS No. | 909089-13-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 53 mg/mL (185.1 mM)
Ethanol: 53 mg/mL (185.1 mM)
H2O: < 1 mg/mL (insoluble or slightly soluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / Ethanol | 1 mM | 3.493 mL | 17.4648 mL | 34.9296 mL | 87.324 mL |
5 mM | 0.6986 mL | 3.493 mL | 6.9859 mL | 17.4648 mL | |
10 mM | 0.3493 mL | 1.7465 mL | 3.493 mL | 8.7324 mL | |
20 mM | 0.1746 mL | 0.8732 mL | 1.7465 mL | 4.3662 mL | |
50 mM | 0.0699 mL | 0.3493 mL | 0.6986 mL | 1.7465 mL | |
100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.8732 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SKL2001 909089-13-0 Cytoskeletal Signaling Stem Cells Wnt/beta-catenin Inhibitor Wnt Beta catenin β-catenin SKL-2001 inhibit SKL 2001 inhibitor